AstraZeneca (NASDAQ:AZN) Raised to “Hold” at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca (NASDAQ:AZN) from a sell rating to a hold rating in a research note released on Wednesday morning, MarketBeat Ratings reports.

Other equities analysts have also issued research reports about the company. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. TD Cowen increased their price target on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, AstraZeneca has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Trading Down 3.7 %

Shares of AZN stock opened at $63.85 on Wednesday. The stock has a 50-day simple moving average of $78.45 and a 200 day simple moving average of $78.75. AstraZeneca has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The stock has a market capitalization of $197.97 billion, a P/E ratio of 30.85, a P/E/G ratio of 1.32 and a beta of 0.47. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69.

Institutional Investors Weigh In On AstraZeneca

Hedge funds have recently bought and sold shares of the business. McClarren Financial Advisors Inc. lifted its stake in AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares in the last quarter. GHP Investment Advisors Inc. purchased a new stake in shares of AstraZeneca during the 2nd quarter worth about $26,000. Capital Performance Advisors LLP purchased a new stake in shares of AstraZeneca during the 3rd quarter worth about $28,000. Pathway Financial Advisers LLC purchased a new stake in shares of AstraZeneca during the 1st quarter worth about $29,000. Finally, Hobbs Group Advisors LLC purchased a new stake in shares of AstraZeneca during the 2nd quarter worth about $35,000. 20.35% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.